Key takeaway: Jagsonpal Pharmaceuticals Limited held its Q1 FY27 Earnings Conference Call on July 30, 2026, where management reported a 9% growth in sales, translating to a 21% increase in operating EBITDA and a 22% rise in net profits. The company highlighted its acquisition of a controlling stake in Aequitas Healthcare, which is anticipated to enhance its presence in the hospital segment. Management noted that the share buyback of Rs.40 crores was completed, with a strong subscription rate. The call emphasized a strategic shift towards higher-value therapies and brand-centric marketing. Management also discussed operational improvements and the integration of Aequitas, projecting significant synergies over the next 36 months. The company aims to achieve Rs.10 crores in EBITDA from Aequitas by the second year post-acquisition. Overall, the management expressed confidence in the company's growth trajectory and operational strategies.

Key takeaway: Jagsonpal Pharmaceuticals Limited held its Q4 FY26 Earnings Conference Call on April 28, 2026, where management reported a return to growth after two quarters of sluggish performance. Managing Director Manish Gupta noted that the company outperformed the Indian Pharmaceutical Market (IPM) growth of 7-8% with a 14.2% growth in Q4. For FY26, revenue grew by approximately 7%, while net profit increased by 19% before exceptional items. The company announced a buyback of INR40 crores and a 200% dividend, including a special dividend of 75%. Chief Operating Officer Amrut Medhekar highlighted improvements in operational performance and MR productivity, while Chief Financial Officer Nirav Vora discussed strong financial metrics, including a 31% increase in PAT for Q4. The management emphasized a focus on organic growth, disciplined cost management, and strategic capital allocation to enhance shareholder value.